BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing

We examined whether the multikinase inhibitor sorafenib and histone deacetylase inhibitors (HDACI) interact to kill pancreatic carcinoma cells and determined the impact of inhibiting BCL-2 family function on sorafenib and HDACI lethality. The lethality of sorafenib was enhanced in pancreatic tumor c...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Martin, Aditi Pandya, Park, Margaret A., Mitchell, Clint, Walker, Teneille, Rahmani, Mohamed, Thorburn, Andrew, Häussinger, Dieter, Reinehr, Roland, Grant, Steven, Dent, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Pharmacology and Experimental Therapeutics 2009
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2713125/
https://ncbi.nlm.nih.gov/pubmed/19483105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.109.056309
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak